A New York hospital has declared a patient cured of sickle-cell anemia, a genetic disorder that primarily affects individuals of African heritage. The breakthrough Lyfgenia treatment has successfully reduced or eliminated the painful symptoms associated with the disease. The patient, Sebastien Beauzile, 21, is the first New Yorker to receive this treatment, developed by Bluebird Bio. The treatment involves introducing healthy adult hemoglobin from a donor into the patient’s bone marrow, effectively curing the disease. Doctors believe that Lyfgenia will replace bone marrow transplants as the primary treatment for sickle cell anemia.
